Fluvoxamine for COVID-19: real-time analysis of all 3 studies

Download Image


4/20	Review	Sukhatme et al., Front. Pharmacol., doi:10.3389/fphar.2021.652688 (Review) (Peer Reviewed)	review	Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
	Details Review of mechanisms of action of fluvoxamine and other SSRIs that could be beneficial for COVID-19 treatment, including lower platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, reg..
4/20	Details Source PDF Review Review
	Sukhatme et al., Front. Pharmacol., doi:10.3389/fphar.2021.652688 (Review) (Peer Reviewed)
	Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
	Review of mechanisms of action of fluvoxamine and other SSRIs that could be beneficial for COVID-19 treatment, including lower platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, regulation of inositol-requiring enzyme 1α-driven inflammation, and increased melatonin levels. Sukhatme et al., 4/20/2021, peer-reviewed, 4 authors.
	Share Tweet Submit Corrections or Comments
3/6	Review	Kirsch, S. (Review) (Preprint)	review	COVID FAQ
	Details COVID FAQ from the founder of the COVID-19 Early Treatment Fund [1], including an extensive analysis of the fluvoxamine trials and other supporting evidence.
3/6	Details Source PDF Review Review
	Kirsch, S. (Review) (Preprint)
	COVID FAQ
	COVID FAQ from the founder of the COVID-19 Early Treatment Fund [1], including an extensive analysis of the fluvoxamine trials and other supporting evidence. [1] treatearly.org/ Kirsch et al., 3/6/2021, preprint, 1 author.
	Share Tweet Submit Corrections or Comments
2/1	Early	Seftel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab050 (Peer Reviewed)	death/ICU, ↓83.9%, p=0.15	Prospective cohort of fluvoxamine for early treatment of COVID-19
	Details Prospective quasi-randomized (patient choice) study with 125 outpatients, 77 treated with fluvoxamine, showing lower death/ICU admission (0 of 77 vs. 2 of 48), lower hospitalization (0 of 77 vs. 6 of 48), and faster recovery with treatmen..
2/1	Details Source PDF Early treatment study Early treatment study
	Seftel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab050 (Peer Reviewed)
	Prospective cohort of fluvoxamine for early treatment of COVID-19
	Prospective quasi-randomized (patient choice) study with 125 outpatients, 77 treated with fluvoxamine, showing lower death/ICU admission (0 of 77 vs. 2 of 48), lower hospitalization (0 of 77 vs. 6 of 48), and faster recovery with treatment. Note that 12 treatment patients were added but are not reflected in the table in the paper (because the numbers had been previously published and the IRB did not allow updating the table). risk of combined death/ICU, 83.9% lower, RR 0.16, p = 0.15, treatment 0 of 77 (0.0%), control 2 of 48 (4.2%), continuity correction due to zero event. risk of hospitalization, 94.0% lower, RR 0.06, p = 0.003, treatment 0 of 77 (0.0%), control 6 of 48 (12.5%), continuity correction due to zero event. risk of no recovery, 98.7% lower, RR 0.01, p < 0.001, treatment 0 of 77 (0.0%), control 29 of 48 (60.4%), continuity correction due to zero event. Seftel et al., 2/1/2021, prospective quasi-randomized (patient choice), USA, North America, peer-reviewed, 2 authors.
	Share Tweet Submit Corrections or Comments
11/12	Early	Lenze et al., JAMA, doi:10.1001/jama.2020.22760 (Peer Reviewed)	progression, ↓92.7%, p=0.009	Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
	Details RCT 152 outpatients, 80 treated with fluvoxamine showing lower progression with treatment (0 of 80 versus 6 of 72 control).
11/12	Details Source PDF Early treatment study Early treatment study
	Lenze et al., JAMA, doi:10.1001/jama.2020.22760 (Peer Reviewed)
	Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
	RCT 152 outpatients, 80 treated with fluvoxamine showing lower progression with treatment (0 of 80 versus 6 of 72 control). risk of disease progression, 92.7% lower, RR 0.07, p = 0.009, treatment 0 of 80 (0.0%), control 6 of 72 (8.3%), continuity correction due to zero event, clinical deterioration over 15 days. risk of hospitalization, 82.0% lower, RR 0.18, p = 0.009, treatment 1 of 80 (1.2%), control 5 of 72 (6.9%), COVID-19 hospitalization within 15 days, see supplemental appendix for details. Lenze et al., 11/12/2020, Double Blind Randomized Controlled Trial, peer-reviewed, 11 authors.
	Share Tweet Submit Corrections or Comments
8/17	Late	Hoertel et al., Molecular Psychiatry, doi:10.1038/s41380-021-01021-4 (Peer Reviewed)		Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
	Details Retrospective 7,230 hospitalized COVID-19 patients in France, 345 receiving an antidepressant medication within 48 hours of admission. There was a significant association between antidepressant use and reduced risk of intubation or death ..
8/17	Details Source PDF Late treatment study Late treatment study
	Hoertel et al., Molecular Psychiatry, doi:10.1038/s41380-021-01021-4 (Peer Reviewed)
	Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
	Retrospective 7,230 hospitalized COVID-19 patients in France, 345 receiving an antidepressant medication within 48 hours of admission. There was a significant association between antidepressant use and reduced risk of intubation or death (HR 0.56, p < 0.001). Fluvoxamine is not included because there was only one person taking it in this study. Hoertel et al., 8/17/2020, peer-reviewed, 17 authors.
	Share Tweet Submit Corrections or Comments

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit